Get the Stockscreener App
253.62
1.59%
3.97
After Hours:
253.60
-0.02
-0.01%
Biogen Inc stock is traded at $253.62, with a volume of 1.30M.
It is up +1.59% in the last 24 hours and up +12.28% over the past month.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
See More
Previous Close:
$249.65
Open:
$255.39
24h Volume:
1.30M
Relative Volume:
0.93
Market Cap:
$37.49B
Revenue:
$9.60B
Net Income/Loss:
$1.37B
P/E Ratio:
27.22
EPS:
9.3182
Net Cash Flow:
$2.32B
1W Performance:
+1.17%
1M Performance:
+12.28%
6M Performance:
+33.99%
1Y Performance:
+69.52%
1-Day Range:
$251.19
$258.73
1-Week Range:
$243.03
$258.78
52-Week Range:
$138.00
$258.78
Biogen Inc Stock (BIIB) Company Profile
Name
Biogen Inc
Sector
Industry
Phone
(781) 464-2000
Address
225 BINNEY STREET, CAMBRIDGE, MA
Compare BIIB vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
253.62 | 37.49B | 9.60B | 1.37B | 2.32B | 9.3182 |
LLY
Lilly Eli Co
|
1,417.54 | 1.26T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
273.20 | 657.68B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
294.89 | 521.11B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
149.52 | 368.89B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
160.79 | 303.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-12-26 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-13-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jul-13-26 | Upgrade | Truist | Hold → Buy |
| Jun-08-26 | Upgrade | Needham | Hold → Buy |
| May-15-26 | Resumed | Evercore ISI | Outperform |
| Apr-22-26 | Upgrade | UBS | Neutral → Buy |
| Apr-20-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Apr-14-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-09-26 | Reiterated | H.C. Wainwright | Buy |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Downgrade | HSBC Securities | Hold → Reduce |
| Nov-06-25 | Upgrade | Stifel | Hold → Buy |
| Sep-25-25 | Initiated | Jefferies | Buy |
| Jul-21-25 | Resumed | Truist | Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Apr-04-25 | Downgrade | Argus | Buy → Hold |
| Feb-11-25 | Initiated | Bernstein | Mkt Perform |
| Jan-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-18-24 | Downgrade | Needham | Buy → Hold |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-31-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Feb-14-24 | Reiterated | Needham | Buy |
| Feb-14-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-24-24 | Downgrade | UBS | Buy → Neutral |
| Dec-20-23 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-07-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-24-23 | Reiterated | UBS | Buy |
| May-01-23 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-17-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-26-22 | Upgrade | Goldman | Neutral → Buy |
| Oct-13-22 | Upgrade | Stifel | Hold → Buy |
| Oct-07-22 | Upgrade | Argus | Hold → Buy |
| Sep-28-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Sep-28-22 | Upgrade | Mizuho | Neutral → Buy |
| Sep-28-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-18-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-22 | Downgrade | Stifel | Buy → Hold |
| Mar-03-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-04-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-04-22 | Reiterated | Barclays | Equal Weight |
| Feb-04-22 | Reiterated | BofA Securities | Neutral |
| Feb-04-22 | Reiterated | Cowen | Outperform |
| Feb-04-22 | Reiterated | Morgan Stanley | Overweight |
| Feb-04-22 | Reiterated | Needham | Buy |
| Feb-04-22 | Reiterated | Oppenheimer | Outperform |
| Feb-04-22 | Reiterated | RBC Capital Mkts | Sector Perform |
| Feb-04-22 | Reiterated | Robert W. Baird | Neutral |
| Feb-04-22 | Reiterated | Wedbush | Neutral |
| Feb-04-22 | Reiterated | Wells Fargo | Equal Weight |
| Feb-04-22 | Reiterated | Wolfe Research | Peer Perform |
| Jan-13-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-12-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-18-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-14-21 | Reiterated | Truist | Buy |
| Jun-11-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Jun-10-21 | Upgrade | UBS | Neutral → Buy |
| Jun-08-21 | Upgrade | Atlantic Equities | Underweight → Neutral |
| Jun-08-21 | Reiterated | Barclays | Equal Weight |
| Jun-08-21 | Upgrade | Citigroup | Sell → Neutral |
| Jun-08-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-08-21 | Reiterated | Jefferies | Buy |
| Jun-08-21 | Reiterated | Morgan Stanley | Overweight |
| Jun-08-21 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-08-21 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Jun-08-21 | Reiterated | Stifel | Buy |
| Jun-08-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-07-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-07-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-07-21 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-05-21 | Downgrade | DZ Bank | Buy → Hold |
| Jan-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-10-20 | Upgrade | DZ Bank | Hold → Buy |
| Nov-09-20 | Downgrade | Atlantic Equities | Neutral → Underweight |
| Nov-09-20 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-09-20 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-04-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Nov-04-20 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Jul-27-20 | Upgrade | Morgan Stanley | Underweight → Overweight |
| Jun-22-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-22-20 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jun-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Apr-23-20 | Downgrade | Citigroup | Neutral → Sell |
| Apr-23-20 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-27-20 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-13-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Dec-02-19 | Downgrade | Robert W. Baird | Neutral → Underperform |
View All
Biogen Inc Stock (BIIB) Latest News
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened - Zacks Investment Research
Big Day for Econ Data, Hyperscaler Earnings - Zacks Investment Research
How Are LLY's Neuroscience and Immunology Drugs Poised Ahead of Q3? - Zacks Investment Research
Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue Estimates - Zacks Investment Research
Boeing Stock Drops 7.5% After Q3 Earnings Miss Erases $10 Billion - 24/7 Wall St.
Biogen schedules October 28 results. Biogen stock trades 0.62 percent below its 52-week high - ad-hoc-news.de
Which Biotech ETF Is the Better Buy: VanEck’s BBH or Invesco’s Factor-Driven PBE? - The Motley Fool
Baron Health Care Fund: Q3 2026 New Positions And Exits - Seeking Alpha
Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains? - Zacks Investment Research
Chubb Breaks to a New 52-Week High at $363.95 - 24/7 Wall St.
Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight - GlobeNewswire Inc.
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Zacks Investment Research
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research
4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch Now - Zacks Investment Research
AbbVie's Neuroscience Franchise: What to Expect Ahead of Q3 Results - Zacks Investment Research
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? - Zacks Investment Research
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Zacks Investment Research
Citigroup Drops 5% After Hours on Earnings Day - 24/7 Wall St.
Cisco Systems (CSCO) Stock Price, News & Analysis - 24/7 Wall St.
Lori Trahan Stock Trades and Disclosures - TechGraph
Daniel S Sullivan Stock Trades and Disclosures - TechGraph
Daniel S Sullivan Stock Trades and Disclosures - TechGraph
Form 4 Boeing Co For: 7 October By Investing.com - Investing.com UK
Brookfield Renewable Partners (BEP) Stock Price, News & Analysis - 24/7 Wall St.
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Cisco Systems Surges 4.2% to $118.31 in a Single Session - 24/7 Wall St.
Biogen's Chief Accounting Officer Sean Godbout Reports October 2026 Stock Transactions via Form 4 - Kalkine Media
Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise? - Zacks Investment Research
Form 4 Boeing Co For: 26 September By Investing.com - Investing.com Nigeria
Form 4 Boeing Co For: 26 September - Investing.com India
Boeing Company (BA) Stock News & Articles - 247wallst.com
Biogen Inc. (BIIB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook - The Motley Fool
Is Biogen Stock Outperforming the S&P 500? - Barchart.com
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology - Yahoo Finance
Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st
Biogen (BIIB) Sees Canada Back LEQEMBI As Fair Value Stays In Focus - simplywall.st
Alzheimer’s Disease Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Alpha Cognition, Biogen, Eisai, Eli Lilly, Otsuka Pharma, Lundbeck, Suven Life Sciences, Roche - Barchart.com
Multiple Sclerosis Market Outlook 2036: Growth Trends, Competitive Landscape, and Future Opportunities by 2034 – DelveInsight | Biogen, Immune Response BioPharma, ImCyse, Atara Bio, Emerald Health - Barchart.com
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
BIIB Maintained by HSBC -- Price Target Raised to $175 - GuruFocus
Biogen Inc. stock gains on fresh analyst upgrades and strong Q2 figures - ad-hoc-news.de
Stifel reiterates Biogen stock rating on immunology pipeline - investing.com
Stifel reiterates Biogen stock rating on immunology pipeline By Investing.com - Investing.com Canada
Stifel reiterates Biogen stock rating on immunology pipeline - Investing.com
Can Biogen (NASDAQ:BIIB) Stay Resilient As Inflation Rises? - Kalkine Media
Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com Canada
Biogen at Wells Fargo healthcare conference: growth bets widen By Investing.com - Investing.com India
Biogen Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Learn Why The Bull Case For Biogen Stock Could Change Following Canada Reimbursement Backing - simplywall.st
Biogen Inc Stock (BIIB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Biogen Inc Stock (BIIB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Minor Lloyd | Director |
Aug 04 '26 |
Proposed Sale |
200.96 |
593 |
119,169 |
0 |
| Minor Lloyd | Director |
Aug 04 '26 |
Sale |
200.96 |
593 |
119,169 |
2,689 |
| Minor Lloyd | Director |
Aug 03 '26 |
Sale |
203.34 |
593 |
120,581 |
3,282 |
| Minor Lloyd | Director |
Aug 03 '26 |
Proposed Sale |
203.34 |
593 |
120,581 |
0 |
| Pangalos Menelas N | Director |
Jun 09 '26 |
Option Exercise |
0.00 |
2,370 |
0 |
2,370 |
| Keeney Adam | Head of Corporate Development |
May 01 '26 |
Option Exercise |
0.00 |
939 |
0 |
6,820 |
| Godbout Sean | Chief Accounting Officer |
Apr 01 '26 |
Option Exercise |
0.00 |
181 |
0 |
1,396 |
| Murphy Nicole | Head of Pharm Ops and Tech |
Feb 12 '26 |
Buy |
195.03 |
3 |
585 |
19,611 |
| Singhal Priya | Officer |
Feb 09 '26 |
Proposed Sale |
199.83 |
2,660 |
531,548 |
0 |
| Singhal Priya | Head of Development |
Feb 09 '26 |
Sale |
199.83 |
2,660 |
531,548 |
8,043 |
0.75%
4.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):